News Celgene MS pill can't beat older rival on disability progres... Phase 3 trial meets main efficacy endpoint, but disability progression stats cause concern.
News Virtual reality stroke rehab platform gets FDA clearance MindMotion Pro helps with upper-limb rehabilitation following a stroke.
News Data keeps Lilly in race for new migraine treatment Company still in race to develop CGRP inhibitor for migraine.
News Ionis hit by safety concerns, rivals Alnylam benefit Biotech insists drug for rare inherited disorder is still approvable.
News Laquinimod failure is bad news for Teva's MS hopes Teva has been forced to abandon laquinimod in relapsing-remitting multiple sclerosis, after it missed a target related to disability progression in a late stage trial.
Sales & Marketing Biotech is back, with Craig Ackerman In Philadelphia this month, pharmaphorum spoke with Craig Ackerman, a partner at the Alexander Group, about launches, AI best practices, and more.
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.
